By Rachel Slajda ( January 28, 2013, 7:19 PM EST) -- The European Medicines Agency on Monday announced that it will review the risks associated with third- and fourth-generation combined oral contraceptives, such as Yaz, after French regulators raised concerns that the drugs carry a higher risk of blood clots and should be restricted....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.